In the recent past years, many discoveries in the tumor microenvironment have led to changes in the management of melanoma and it is rising up hopes, specially, to those in advanced stages. FDA approved seven new drugs from 2011 to 2014. They are: Vemurafenib, Dabrafenib and Trametinib, kinases inhibitors used for patients that have BRAFV600E mutation; Ipilimumab (anti-CTLA4), Pembrolizumab (anti-PD-1) and Nivolumab (anti-PD-1), monoclonal antibodies that stimulate the immune system; and Peginterferon alfa-2b, an anti-proliferative cytokine used as adjuvant therapy. In this article, we will review the molecular bases for these new metastatic melanoma therapeutic agents cited above and also analyze new molecular discoveries in melanoma study, as Cancer-Testis antigens (CT). They are capable of induce humoral and cellular immune responses in cancer patients and because of this immunogenicity and their restrict expression in normal tissues, they are considered an ideal candidate for vaccine development against cancer. Among CT antigens, NY-ESO-1 is the best characterized in terms of expression patterns and immunogenicity. It is expressed in 20-40% of all melanomas, more in metastatic lesions than in primary ones, and it is very heterogeneous inter and intratumoral. Breslow index is associate with NY-ESO-1 expression in primary cutaneous melanomas, but its relation to patient survival remains controversial.
INTRODUCTION
Melanoma has received considerable attention and has been addressed in several studies due to the increase in incidence and mortality rates worldwide, especially in individuals with white skin. 1, 2 In
Brazil, there will be 3 to 4 new cases/ 100,000 inhabitants according to the National Cancer Institute (INCA) in 2016, totaling 5,670 new cases. 3 In the US, 76,380 new cases of melanoma are estimated this year. 4 The various findings of recent years through studies of the tumor microenvironment already cause changes in the therapeutic approach and raise hopes for better management of patients with melanoma, especially those in the more advanced stages of the dis- sponse, controlling the growth and spread of cancer. [6] [7] [8] When the tissue microenvironment is not inflammatory, the T cell can differentiate into regulator (Treg), which is important in inhibiting the immune system. Treg cells are a very interesting and promising target in immunotherapy for cancer because they are often present in the tumor, inhibiting the adaptive and innate responses of the host. Treg cells characteristically express the FoxP3 (transcription factor forkhead box protein 3) molecule, which belongs to a large family of different transcription factors, whose function would be primarily regulatory of the immune system. However, CD8+ FoxP3+ cells (double positive) have also been described, whose function has been cytotoxic and non-regulatory, as was imagined.
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The presence of tumor-infiltrating lymphocytes (TIL) in melanoma has been associated with better prognosis in several studies and is interpreted as an indicator that the host is promoting a more effective immune response against the tumor.
10-18 However, other studies have failed to prove this association and the meaning of TIL remains controversial.
Gooden et al., in 2011, conducted a meta-analysis on the prognostic influence of TIL on cancers. 19 The presence of CD3+ and CD8+ cells had a beneficial effect on patient survival, whereas FoxP3+ regulatory cells had no association with overall patient survival. When CD8+/FoxP3+ ratio (effector/regulator) was higher, the association was even greater. However, more studies are needed to corroborate these findings.
NEW THERAPIES FOR METASTATIC MELANOMA AND THEIR

MOLECULAR CHANGES
The drugs approved by the FDA for metastatic melanoma between 2011-2014 and their mechanism of action are summarized in table 1.
Target-therapy
Target therapies are drugs or other substances that block the growth or spread of a cancer by interfering with specific molecules (target molecules) that are involved in the growth, progression, and spread of cancer. 20 They differ from chemotherapy in several ways:
-they act on specific molecules associated with cancer, while most standard chemotherapeutics act on all rapidly dividing cells, whether normal or cancerous.
-they are deliberately chosen or designed to interact with their target, while most chemotherapeutics have been identified because of their ability to kill cells.
-they are often cytostatic (block tumor proliferation) while standard chemotherapy agents are cytotoxic (kill the tumor cell).
Mutations in somatic oncogenes were identified in subgroups of patients with melanoma ( 24 In addition to the adverse events, a major obstacle to the treatment with these drugs is the occurrence of clinical resistance, observed practically on a universal basis. Primary resistance (not being effective in the first cycle), observed in approximately 15% of patients, is less frequent than secondary resistance, when the disease progresses after having had an initial improvement, which happens in the majority of patients.
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IMUNOTHERAPY
By inhibiting immune system checkpoints, immunotherapeutics increase or stimulate "de novo" the antitumor response to kill cancer cells rather than acting directly on them, as do chemotherapeutics and target therapies.
Anti-CTLA4 (Ipilimumab)
This was the first T-cell receptor to be targeted in the clinical treatment of metastatic melanoma. It was approved by the FDA in 2011 and by ANVISA in July 2012. Ipilimumab is a monoclonal antibody intravenously administered at a dose of 3mg/kg every 3 weeks, in a total of 4 doses over 3 months. The role of CTLA4
is to regulate the amplitude of T lymphocyte activation in the beginning of the process. Thus, it uses a costimulation receptor, the CD28. [26] [27] [28] Both share the same ligand CD80 and CD86 (also known as B7.1 and B7.2, respectively). [29] [30] [31] [32] Although the exact mechanism
is not yet known, the CTLA4 receptor, when activated, blocks the activation of T lymphocytes. It seems that its major role is in decreasing the activation of helper T lymphocytes and increasing the regulatory action of regulatory T lymphocytes. Therefore, by inhibiting lymphocyte blockade, the immune system is stimulated to fight the tumor.
More impressive than the benefit in the mean survival of patients was the maintenance of the therapeutic effects for more than 2 years in 18% of the cases, even with the suspension of the treatment.
This would make us suppose that there could be a re-education of the immune system, which would keep the tumor under control. 33 The most important adverse events are autoimmune, such as colitis, hepatitis, skin rash, pneumonitis, neuritis, endocrinopathies and ocular problems. The adverse events of both antibodies in this group are very similar to those of Ipilimumab, but pneumonitis appears to be more prevalent than colitis in anti-PD-1 drugs.
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Anti-PD-L1
Although not yet approved by the FDA, this form of immunotherapy has at least 3 compounds under study aiming at blocking PD-1 axis by inhibiting PD-1, which is one of its ligands. Initially, melanomas, in addition to ovarian and lung cancers, were reported to have a high level of PD-L1 expression in their tumor cells. [42] [43] [44] Later, studies with many other cancers also demonstrated its presence. 40 There appear to be a strong correlation between the expression of PD-L1 on the surface of the tumor cell with the tumor-infiltrating lymphocytes and the expression of gamma interferon intratumor.
This correlation was not only seen with tumors but also at a regional level, where regions with more infiltrates were also the ones that most expressed PD-L1 in the tumor. 45 The other PD-1 ligand, PD-L2, is highly expressed in certain B-cell lymphomas, such as primary mediastinal B-cell lymphoma, follicular B-cell lymphoma, and Hodgkin lymphoma. 46 An anti-PD-L1
antibody blocks the interaction between PD-L1 and CD80 and between PD-1 and PD-L1, but does not prevent PD-1 from binding to PD-L2 (something that would only occur with anti-PD-1 antibodies).
Thus, according to the dominant interaction in a particular cancer, we could choose one or the other antibody, or even both ( Figure 1 ). 52 The number 1 stands for the fact that it was the first discovered member of a new family. The antigen was identified by the SEREX technique. In this methodology, a protein expression library produced from cDNA from an esophageal tumor was screened with autologous serum from patients, allowing the identification of antigens recognized by the humoral immune system. 48 In the following year, Jager et al. were able to isolate CD8 cells from a melanoma patient in who they specifically recognized the NY-ESO-1 antigen. 56 The main product of NY-ESO-1 gene coding is a 180 amino acid protein, with a N-terminal glycine rich and extremely hydrophobic C-terminal region, so insoluble that it could be confused with a transmembrane domain, which there is no evidence. 48 The antigen has mainly cytoplasmic expression.
Little is known about its function and its involvement in the tumor genesis. This lack of information is due to the fact that there are no corresponding genes in model organisms, such as drosophila and rodents, which makes it impossible to perform knockout tests.
CT antigens are mostly exclusive to primates, making it difficult to conduct pre-clinical trials of therapeutic vaccines in animal models. 57 In normal human tissues, the expression of NY-ESO-1 is restricted to spermatogonia of the adult testis and gradually decreases with maturation and differentiation of germ cells. It is detected in 20% to 30% of lung, esophagus, liver, stomach, prostate, ovary, bladder and melanoma tumors (see below). 43, [58] [59] [60] [61] [62] [63] Although rare, but very aggressive, synovial sarcoma presents about 80% positivity for NY-ESO-1, with an intense and homogeneous distribution throughout the tumor. 64 In myxoid and round cell liposarcomas, its expression is around 90%. 65 However, its frequency is low in colorectal tumors, pancreas tumors, kidney tumors and lymphomas.
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Antigen NY-ESO-1 in melanoma
The analysis of the molecular aspects of melanoma has assumed increasing importance for the understanding of its various subtypes, aiming at a more specific treatment for the different phenotypes, and at a better outcome. Regarding the analysis of NY-ESO-1 in benign melanocytic tumors, two studies were conducted with 19 and 20 nevi each, and in none of them there was expression of this antigen, whether dysplastic, dermal, Spitz, junctional or compound nevi. 70, 71 It was postulated by the authors that NY-ESO-1 could aid in the differential diagnosis between benign nevi and melanomas.
In a recent study, only an in situ melanoma expressed the NY-ESO-1 protein (1/10) and the melanomas in the radial growth phase were all negative for the antigen (0/11). The frequency of NY-ESO-1 in melanomas in the vertical growth phase was 24% (16/68). 71 Goydos et al. published, in 2001, a study in which 52 melanomas were analyzed, 20 of them were primary, 22 were locoregional metastases, and 10 were distant metastases for the presence of NY-ESO-1 by the PCR method. 72 Overall, 33% (17/52) of melanomas 75 Differences in the frequency of NY-ESO-1 among the findings of the different studies may be due not only to the stage of melanoma (primary x metastatic) but also to the method used (PCR x immunohistochemistry) and to the cut-off used to consider the tumor as positive or negative. Table 3 summarizes the findings regarding the expression of NY-ESO-1 in melanoma until the present.
This expression seems to be more frequent in tumors of more advanced stages, associated to the progression of melanocytic tumors. 71 It is not possible, however, to determine if antigen expression causes melanoma to progress or if the tumor, when progressing, starts to presenting new antigens, including NY-ESO-1.
As for the distribution of the antigen in melanoma tumor cells, there is no concordance between the studies in the literature. There was no significant association between NY-ESO-1 and age at diagnosis of primary melanoma or skin phototype either at the site of tumor onset, according to two studies that attempted to correlate these variables. 71, 75 In the analysis of the histological type, the superficial extensive type was negatively associated with the presence of NY-ESO-1 when compared with other histological types together (p<0.02).
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Another study, published in 2011, found no association between these two variables. 75 Emerging knowledge of genomic differences between melanoma subtypes, with the extensive superficial type most often harboring the BRAFV600E mutation compared with the other melanoma subtypes, is interesting in this context.
There is an association between Breslow index and NY-ESO-1 expression in primary invasive skin melanomas (p = 0.007). 71 Other similar results have been published. A study evaluated 251 primary melanomas and showed increased expression of NY-ESO-1 in the intermediate group between 1.1-4.0mm thickness compared with the thinner ones, less than 1.1mm. 73 In another study, examining 61 primary skin melanomas, the mean thickness of the positive tumors was 4.7mm versus 1.53mm in the negative. 74 More recently, in 2011, a survey of 321 melanomas showed a greater expression of NY-ESO-1 antigen with increased melanoma thickness. When analyzing the presence of ulceration in the tumor in relation to the positivity of the NY-ESO-1 protein, two studies evidenced a tendency to positive association, but there was no statistical significance. 71, 75 The number of mitoses in melanoma was not associated with the presence of NY-ESO-1 in the only study in which it was tested.
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Although investigations indicate that the presence of NY-ESO-1 is associated with thicker tumors, and these are more frequently causing metastasis, there was no statistical difference in sentinel lymph node status or in the development of metastases of patients in relation to the presence of the antigen. 71, 75 As for disease-specific survival of patients, most studies have the results obtained were even better. 101 Other research has demonstrated effective inhibition of tumorigenesis and melanoma growth by using a novel NY-ESO-1 based vaccine and an aluminum-polysaccharide-HH2 adjuvant. 102 Finally, a Brazilian study that promoted the blockade of CTLA4 and effected the vaccination with attenuated protozoa of Trypanosoma cruzi, expressing NY-ESO-1, was able to induce both the effector function of CD8+ lymphocytes and memory. 
